On May 28, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported a significant expansion of new indications to its AI-enabled Next platform ahead of the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. Next establishes a new category of "real-time clinical intelligence" — a departure from legacy retrospective analyses and generic EHR alerts — designed to facilitate the delivery of precision medicine.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To demonstrate the real-world impact of these expanded capabilities, Tempus will showcase a landmark study at ASCO (Free ASCO Whitepaper) 2026, describing clinically meaningful improvements in rates of biomarker testing for early-stage non-small cell lung cancer (eNSCLC) after the implementation of Tempus Next. The multi-center prospective study evaluated the deployment of the Tempus Next AI-enabled clinical decision support system (AI-CDSS) across 662 eNSCLC patients at six diverse U.S. community health systems.
The Next platform drove significant behavioral change and successfully closed critical care gaps by analyzing unstructured EHR data to identify patients who did not receive guideline-directed biomarker testing. Key findings from the study include:
The implementation of real-time interventions delivered an absolute testing rate lift of +24% for ALK, +18% for EGFR, and +13% for PD-L1 within 90 days of pathologic diagnosis.
The program translated testing directly into optimized therapy management, with 89% of treated patients receiving guideline-concordant therapy.
The expanded platform will surface insights from patients across six new clinical scenarios in breast, colorectal, ovarian, prostate, and urothelial cancers. Furthermore, Next has introduced a suite of advanced intelligence capabilities that enable precision medicine teams to map patient experiences and develop targeted care gap programs that support their institution’s health equity initiatives.
"The true challenge in precision oncology is the data fragmentation that hides critical care gaps across the patient journey," said Ryan Fukushima, CEO of Data and Apps at Tempus. "By expanding Next, we are providing our health systems partners with a 360-degree view to not only identify these gaps but to quantify the truly addressable opportunities for intervention. Our goal is to ensure that clinical innovation reaches every patient, closing the gap between the latest biomarker-driven therapies and community-level care to improve outcomes at scale."
(Press release, Tempus, MAY 28, 2026, View Source [SID1234666169])